Form 4: QCLS Director Glass Granted 11,420 RSUs

Q/C Technologies, Inc. Director and Chief Medical Officer Mitchell Glass was granted 11,420 Restricted Stock Units, which vested immediately upon stockholder approval of a plan amendment.

Summary

• Mitchell Glass, a Director and Chief Medical Officer of Q/C Technologies, Inc. (QCLS), acquired 11,420 shares of common stock.
• The acquisition was a grant of Restricted Stock Units (RSUs) at a price of $0 per share.
• The RSUs were initially granted on October 3, 2025, contingent on stockholder approval of an amendment to the Q/C Technologies, Inc. 2021 Equity Incentive Plan.
• Stockholders approved the Plan Amendment on November 14, 2025, at which point the RSUs vested immediately.
• Following this transaction, Mitchell Glass beneficially owns a total of 12,500 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is generally a positive sign of management alignment and retention, though it represents a minor dilution. Stockholder approval of the plan amendment is also a positive governance signal.

Positives

• The grant of 11,420 Restricted Stock Units to a key executive and director, Mitchell Glass, aligns his interests with shareholders.
• Stockholder approval of the 2021 Equity Incentive Plan amendment demonstrates support for the company's compensation strategy.
• Immediate vesting of the RSUs upon approval indicates a clear and immediate incentive for the executive.

Negatives

• The grant of RSUs at a $0 price represents a minor dilution to existing shareholder value, though this is a common form of executive compensation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the completion of the RSU grant.

Industry Context

This Form 4 filing details a routine executive compensation event, specifically an RSU grant, which is a standard practice across various industries to incentivize and retain key management. It does not provide broader industry trend insights.

Comparison to Industry Standards

• Executive equity grants, such as Restricted Stock Units (RSUs), are a common component of compensation packages for directors and officers in publicly traded companies across all sectors.
• The grant of 11,420 RSUs to a Chief Medical Officer and Director at a company like Q/C Technologies, Inc. is consistent with typical practices aimed at aligning management incentives with shareholder interests.
• Specific comparable companies or projects are not detailed in this filing, but similar RSU grants are observed at companies like Pfizer, Johnson & Johnson, or smaller biotech firms, where executive compensation often includes a significant equity component to reward long-term performance and retention.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from the issuance of new shares for the RSU grant, but potentially positive impact from increased executive alignment and retention.
• Employees: May signal a stable compensation strategy and commitment to equity incentives for key personnel.

Key Dates

Recommendation

This Form 4 filing reports a routine RSU grant to a director and officer, which is a standard executive compensation practice. While it indicates management alignment, it does not present new information significant enough to warrant a change in investment recommendation. The transaction is expected and does not alter the fundamental outlook for the company.

Keywords

Q/C Technologies, QCLS, Mitchell Glass, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Equity Incentive Plan, Director Compensation, Chief Medical Officer